199 related articles for article (PubMed ID: 32112821)
1. The diverse functions of Siglec-15 in bone remodeling and antitumor responses.
Kang FB; Chen W; Wang L; Zhang YZ
Pharmacol Res; 2020 May; 155():104728. PubMed ID: 32112821
[TBL] [Abstract][Full Text] [Related]
2. Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase/Akt and Erk pathways in association with signaling Adaptor DAP12.
Kameda Y; Takahata M; Komatsu M; Mikuni S; Hatakeyama S; Shimizu T; Angata T; Kinjo M; Minami A; Iwasaki N
J Bone Miner Res; 2013 Dec; 28(12):2463-75. PubMed ID: 23677868
[TBL] [Abstract][Full Text] [Related]
3. Molecular structure, expression, and the emerging role of Siglec-15 in skeletal biology and cancer.
Rashid S; Song D; Yuan J; Mullin BH; Xu J
J Cell Physiol; 2022 Mar; 237(3):1711-1719. PubMed ID: 34893976
[TBL] [Abstract][Full Text] [Related]
4. Siglec-15 is a potential therapeutic target for postmenopausal osteoporosis.
Kameda Y; Takahata M; Mikuni S; Shimizu T; Hamano H; Angata T; Hatakeyama S; Kinjo M; Iwasaki N
Bone; 2015 Feb; 71():217-26. PubMed ID: 25460183
[TBL] [Abstract][Full Text] [Related]
5. Involvement of Siglec-15 in regulating RAP1/RAC signaling in cytoskeletal remodeling in osteoclasts mediated by macrophage colony-stimulating factor.
Kobayashi H; Terkawi MA; Ota M; Hasegawa T; Yamamoto T; Shimizu T; Sato D; Fujita R; Murakami T; Amizuka N; Iwasaki N; Takahata M
Bone Res; 2024 Jun; 12(1):35. PubMed ID: 38849345
[TBL] [Abstract][Full Text] [Related]
6. The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway.
Takamiya R; Ohtsubo K; Takamatsu S; Taniguchi N; Angata T
Glycobiology; 2013 Feb; 23(2):178-87. PubMed ID: 23035012
[TBL] [Abstract][Full Text] [Related]
7. Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) mediates periarticular bone loss, but not joint destruction, in murine antigen-induced arthritis.
Shimizu T; Takahata M; Kameda Y; Endo T; Hamano H; Hiratsuka S; Ota M; Iwasaki N
Bone; 2015 Oct; 79():65-70. PubMed ID: 26027508
[TBL] [Abstract][Full Text] [Related]
8. Siglec-15 as multifunctional molecule involved in osteoclast differentiation, cancer immunity and microbial infection.
Huang R; Zheng J; Shao Y; Zhu L; Yang T
Prog Biophys Mol Biol; 2023 Jan; 177():34-41. PubMed ID: 36265694
[TBL] [Abstract][Full Text] [Related]
9. The human sialic acid-binding immunoglobulin-like lectin Siglec-9 and its murine homolog Siglec-E control osteoclast activity and bone resorption.
Andes FT; Adam S; Hahn M; Aust O; Frey S; Grueneboom A; Nitschke L; Schett G; Steffen U
Bone; 2021 Feb; 143():115665. PubMed ID: 33007530
[TBL] [Abstract][Full Text] [Related]
10. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy.
Wang J; Sun J; Liu LN; Flies DB; Nie X; Toki M; Zhang J; Song C; Zarr M; Zhou X; Han X; Archer KA; O'Neill T; Herbst RS; Boto AN; Sanmamed MF; Langermann S; Rimm DL; Chen L
Nat Med; 2019 Apr; 25(4):656-666. PubMed ID: 30833750
[TBL] [Abstract][Full Text] [Related]
11. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
Cai X; Xing J; Long CL; Peng Q; Humphrey MB
J Bone Miner Res; 2017 Nov; 32(11):2207-2218. PubMed ID: 28650106
[TBL] [Abstract][Full Text] [Related]
12. Impaired osteoclast differentiation and function and mild osteopetrosis development in Siglec-15-deficient mice.
Hiruma Y; Tsuda E; Maeda N; Okada A; Kabasawa N; Miyamoto M; Hattori H; Fukuda C
Bone; 2013 Mar; 53(1):87-93. PubMed ID: 23238125
[TBL] [Abstract][Full Text] [Related]
13. Siglecs that Associate with DAP12.
Angata T
Adv Exp Med Biol; 2020; 1204():215-230. PubMed ID: 32152949
[TBL] [Abstract][Full Text] [Related]
14. Siglec-15, a member of the sialic acid-binding lectin, is a novel regulator for osteoclast differentiation.
Hiruma Y; Hirai T; Tsuda E
Biochem Biophys Res Commun; 2011 Jun; 409(3):424-9. PubMed ID: 21586272
[TBL] [Abstract][Full Text] [Related]
15. Siglec-15: a potential regulator of osteoporosis, cancer, and infectious diseases.
Angata T
J Biomed Sci; 2020 Jan; 27(1):10. PubMed ID: 31900164
[TBL] [Abstract][Full Text] [Related]
16. Enhancing the Anti-tumor Potency of a Novel Siglec-15 Antibody by Engineering its Fc-mediated Effector Functions.
Ding H; Yao B; Ci L; Feng J; Ouyang P; Chen G; Hui X; Zhou D
J Immunother; 2023 Jun; 46(5):161-169. PubMed ID: 37103472
[TBL] [Abstract][Full Text] [Related]
17. A Comprehensive Review of Immunoreceptor Regulation of Osteoclasts.
Humphrey MB; Nakamura MC
Clin Rev Allergy Immunol; 2016 Aug; 51(1):48-58. PubMed ID: 26573914
[TBL] [Abstract][Full Text] [Related]
18. Siglec-15-targeting therapy increases bone mass in rats without impairing skeletal growth.
Sato D; Takahata M; Ota M; Fukuda C; Tsuda E; Shimizu T; Okada A; Hiruma Y; Hamano H; Hiratsuka S; Fujita R; Amizuka N; Hasegawa T; Iwasaki N
Bone; 2018 Nov; 116():172-180. PubMed ID: 30076992
[TBL] [Abstract][Full Text] [Related]
19. N-glycosylation of Siglec-15 decreases its lysosome-dependent degradation and promotes its transportation to the cell membrane.
Chen X; Dang X; Song J; Wang G; Liu C; Cui L; Huang Z
Biochem Biophys Res Commun; 2020 Nov; 533(1):77-82. PubMed ID: 32921411
[TBL] [Abstract][Full Text] [Related]
20. Natural receptor-based competitive immunoelectrochemical assay for ultra-sensitive detection of Siglec 15.
Zhu Z; Zhu J; Zhao J; Zhu K; Xu Q; Chen H
Biosens Bioelectron; 2020 Mar; 151():111950. PubMed ID: 31868605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
